Thoratec Corporation

Skip to content

2015 Press Releases

Keyword Search

2015 | 2014 | 2013 | 2012 | 2011
DateTitle 
08/21/15Thoratec Announces End Of "Go Shop" Period
PLEASANTON, Calif., Aug. 21, 2015 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in mechanical circulatory support therapies to save, support and restore failing hearts, announced today the expiration of the "go shop" period included in the previously announced definitive merger agreement with St. Jude Medical.  Thoratec and its representatives solicited alternative acquisition proposals during the go shop period.  No acquisition proposals were received and the merger with S... 
Printer Friendly Version
08/04/15Thoratec® Reports Second Quarter 2015 Results
- Revenue of $128.7 million for the second quarter of 2015 - Worldwide HeartMate pump unit growth of 20% - GAAP net income per diluted share of $0.24, and non-GAAP net income per diluted share of $0.37 - No financial guidance due to pending transaction PLEASANTON, Calif., Aug. 4, 2015 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in mechanical circulatory support (MCS) therapies to save, support and restore failing hearts, today reported its financial results fo... 
Printer Friendly Version
07/22/15St. Jude Medical and Thoratec Announce Definitive Agreement
Combination Accelerates Innovation-Based Growth Program and Expands Heart Failure Franchise St. Jude Medical Will Discuss Transaction on its Second Quarter 2015 Earnings Call Scheduled for 8 a.m. EDT (7 a.m. CDT) on July 22, 2015 ST. PAUL, Minn. & PLEASANTON, Calif.--(BUSINESS WIRE)--Jul. 22, 2015-- St. Jude Medical (NYSE:STJ) and Thoratec (NASDAQ:THOR) today announced that the Boards of Directors of both companies have unanimously approv... 
Printer Friendly Version
07/22/15Thoratec Announces Preliminary Second Quarter Revenue
PLEASANTON, Calif., July 22, 2015 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in mechanical circulatory support therapies to save, support and restore failing hearts, announced preliminary unaudited revenue in the range of $128 million to $129 million for the second quarter of 2015. "Our strong second quarter performance resulted from a broad increase in utilization of our products globally, driven in particular by favorable trends in our North American HeartMate franc... 
Printer Friendly Version
07/13/15Thoratec Receives CE Mark Approval For HeartMate PHP™
PLEASANTON, Calif., July 13, 2015 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in mechanical circulatory support therapies to save, support and restore failing hearts, announced that HeartMate PHP (Percutaneous Heart Pump) received CE Mark approval, permitting sale in the European Union and other international countries.  Approval was based on data from the first 30 patients enrolled in the HeartMate PHP SHIELD I CE Mark Trial examining use of PHP to support patients under... 
Printer Friendly Version
07/06/15Thoratec Announces First HeartMate 3™ Implant in European Less Invasive Surgical Trial
PLEASANTON, Calif., July 6, 2015 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in mechanical circulatory support therapies to save, support and restore failing hearts, announced the first ever HeartMate 3™ implant performed via mini-thoracotomy.  This implant begins a European study to evaluate outcomes and complications using less invasive surgical placement through hemi-sternotomy and left thoracotomy techniques.  The study will include ten cases performed at three Europe... 
Printer Friendly Version
05/26/15Thoratec Presentation At Goldman Sachs Healthcare Conference To Be Webcast
PLEASANTON, Calif., May 26, 2015 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in mechanical circulatory support therapies to save, support and restore failing hearts, said today it will participate in the Goldman Sachs 36th Annual Healthcare Conference on Tuesday, June 9. D. Keith Grossman, President and Chief Executive Officer, will provide an update on the company, beginning at 2:00 p.m., Pacific Daylight time (5:00 p.m., Eastern Daylight Time). The presentation wi... 
Printer Friendly Version
05/26/15Thoratec Receives Conditional FDA Approval For The Shield II U.S. Clinical Trial For HeartMate PHP
Live Case Presented at EuroPCR Conference PLEASANTON, Calif., May 26, 2015 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in mechanical circulatory support therapies to save, support and restore failing hearts, announced that the FDA has granted conditional approval for a U.S. IDE clinical trial to investigate use of the HeartMate PHP acute catheter-based heart pump in patients undergoing a high-risk percutaneous coronary intervention. The SHIELD II (Supporting patients u... 
Printer Friendly Version
05/07/15Thoratec® Reports First Quarter 2015 Results
- Revenue of $121.3 million for the first quarter of 2015 - GAAP net income per diluted share of $0.20, and non-GAAP net income per diluted share of $0.38 - Company increases 2015 guidance for revenue to $465 million to $475 million and adjusts guidance for net income per diluted share to $0.58 to $0.68 on a GAAP basis and $1.15 to $1.25 on a non-GAAP basis PLEASANTON, Calif., May 7, 2015 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in mechanical circulatory suppo... 
Printer Friendly Version
05/01/15Thoratec Announces Addition To Senior Management Team
PLEASANTON, Calif., May 1, 2015 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in mechanical circulatory support therapies to save, support and restore failing hearts, announced today that Marta Antonucci has joined Thoratec in the newly created role of President, International. This new Europe-based position is responsible for all Thoratec commercial operations outside of North America, including Europe, Asia, and Latin America, and reports directly to the Chief Executiv... 
Printer Friendly Version
04/30/15Thoratec Presentation At Bank Of America Merrill Lynch Healthcare Conference To Be Webcast
PLEASANTON, Calif., April 30, 2015 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in mechanical circulatory support therapies to save, support and restore failing hearts, said today it will participate in the Bank of America Merrill Lynch 2015 Healthcare Conference on Thursday, May 14. D. Keith Grossman, President and Chief Executive Officer, will provide an update on the company, beginning at 10:40 a.m., Pacific Daylight time (1:40 p.m., Eastern Daylight Time). The pr... 
Printer Friendly Version
04/20/15Thoratec Schedules First Quarter Conference Call, Webcast
PLEASANTON, Calif., April 20, 2015 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today announced that it will report its operating results for the first quarter of fiscal year 2015 on Thursday, May 7. The company will hold a conference call to discuss its financial results and operating activities, open to all interested parties, at 1:30 p.m., Pacific Daylight Time (4:30... 
Printer Friendly Version
04/17/15ROADMAP Study Demonstrates HeartMate II® Benefits In Ambulatory Advanced Heart Failure Patients
PLEASANTON, Calif., April 17, 2015 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today announced results from the ROADMAP Study (Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients). For the primary endpoint, a composite of survival and functional improvement, ROADMAP demonstrated a stat... 
Printer Friendly Version
04/16/15Thoratec Comments On HeartMate II® Data In ENDURANCE Destination Therapy Trial
PLEASANTON, Calif., April 16, 2015 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, commented on HeartMate II clinical data presented as part of the ENDURANCE destination therapy trial today at the 35th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation (ISHLT 2015) in Nice, France.  "We are pleased that the ENDURANCE stu... 
Printer Friendly Version
04/06/15Thoratec To Webcast Investor Meeting At ISHLT Conference
PLEASANTON, Calif., April 6, 2015 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today announced that it will hold a meeting for investors and analysts during the ISHLT 2015 Conference in Nice, France on Friday, April 17. The company update will begin at 5:00 p.m., Central European Summer Time (11:00 a.m., Eastern Daylight Time) and will cover clinical data released at th... 
Printer Friendly Version
04/02/15Thoratec Receives Approval From FDA For Full Expansion Of HeartMate III™ U.S. IDE Clinical Trial
PLEASANTON, Calif., April 2, 2015 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today announced that it received final approval from the FDA to broaden enrollment of the HeartMate III U.S. clinical trial of up to 1,028 patients in up to 60 sites. This was based on the FDA's evaluation of safety data from the first ten HeartMate III implants performed in recent months during... 
Printer Friendly Version
02/25/15Thoratec Announces Presentations At Investor Conferences For March 2015
PLEASANTON, Calif., Feb. 25, 2015 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today it will be participating in two upcoming investor conferences. On Wednesday, March 4, the company will participate in the Raymond James 36th Annual Institutional Investors Conference.  Taylor C. Harris, Vice President and Chief Financial Officer, will provide an update on the compa... 
Printer Friendly Version
02/10/15Thoratec® Reports Fourth Quarter 2014 Results
- Revenue of $128.0 million for the fourth quarter of 2014 - GAAP net income per diluted share of $0.21, and non-GAAP net income per diluted share of $0.39 - Company establishes 2015 guidance for revenue of $450 million to $460 million and net income per diluted share of $0.60 to $0.70 on a GAAP basis and $1.10 to $1.20 on a non-GAAP basis PLEASANTON, Calif., Feb. 10, 2015 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support ... 
Printer Friendly Version
01/30/15Thoratec Presentation At Leerink Global Healthcare Conference To Be Webcast
PLEASANTON, Calif., Jan. 30, 2015 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today it will be participating in the Leerink Global Healthcare Conference on Thursday, February 12. Taylor C. Harris, Vice President and Chief Financial Officer, will provide an update on the company beginning at 10:45 a.m., Eastern Standard Time (7:45 a.m., Pacific Standard Time).  ... 
Printer Friendly Version
01/28/15Thoratec Schedules Fourth Quarter Conference Call, Webcast
PLEASANTON, Calif., Jan. 28, 2015 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today announced that it will report its operating results for the fourth quarter of fiscal year 2014 on Tuesday, February 10. The company will hold a conference call to discuss its financial results and operating activities, open to all interested parties, at 1:30 p.m., Pacific Standard Time ... 
Printer Friendly Version
01/02/15Thoratec Presentation At J.P. Morgan Healthcare Conference To Be Webcast
PLEASANTON, Calif., Jan. 2, 2015 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today it will be participating in the 33rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 14. D. Keith Grossman, President and Chief Executive Officer, will provide an update on the company beginning at 10:00 a.m., Pacific Standard Time (1:00 p.m., Eastern Standard Time). ... 
Printer Friendly Version